Table 4

Determination of CYP Cl_int of individual human CYPs to oxidative metabolism for marker substrates

Compound	CL_int
Compound	CYP1A2	CYP2C9	CYP2C19	CYP2D6	CYP3A4
	μl · min⁻¹pmol⁻¹
Tolbutamide	N.D.^4-a	0.014^4-b	0.03 ± 0.01	N.D.	N.D.
Diazepam	N.D.	N.D.	0.17 ± 0.05	N.D.	N.D.
Metoprolol	N.D.	N.D.	N.D.	1.03 ± 0.07	N.D.
Ibuprofen	N.D.	0.29 ± 0.09	0.17 ± 0.01	N.D.	N.D.
Propranolol	0.34 ± 0.03	N.D.	0.66 ± 0.06	5.07 ± 2.80	N.D.
Dextromethorphan	N.D.	N.D.	0.16 ± 0.10	1.97 ± 0.24	N.D.
Omeprazole	N.D.	N.D.	6.95 ± 1.93	N.D.	0.44 ± 0.06
Diltiazem	N.D.	N.D.	0.30 ± 0.04	N.D.	0.58 ± 0.04
Testosterone	N.D.	N.D.	N.D.	N.D.	0.42 ± 0.03
Verapamil	N.D.	N.D.	N.D.	N.D.	1.19 ± 0.12

↵4-a N.D., not detectable (<0.02 μl · min⁻¹ · pmol⁻¹).
↵4-b Determined fromV_max/K_m. Mean ± S.D. forn = 3 separate experiments.